Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

MadeMed vs Southern Vitality and Weight Loss

Two GLP-1 desks, one scoreboard. We put MadeMed and Southern Vitality and Weight Loss head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 8 · Grade B

MadeMed

Visit MadeMed Full brief →
vs
No. 171 · Grade C

Southern Vitality and Weight Loss

Visit Southern Vitality and Weight Loss Full brief →

The verdict

MadeMed takes this head-to-head.

MadeMed scores 86 to 68 on our six-factor Brief Score — Publishes a price for every dose of every route — which makes it easy to brief, and expensive if you stay low.

That doesn't make Southern Vitality and Weight Loss a bad call — it's best for cost-sensitive shoppers wanting cheap compounded glp-1 from a provider that names its pharmacies. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
92
48
Supply Reliability
84
76
Transparency
94
72
Access Breadth
76
50
Clinical Oversight
84
87
Track Record
82
84
MadeMedBrief Score 86 · 68Southern Vitality and Weight Loss

Price, coverage & the tracker

MadeMedSouthern Vitality and Weight Loss
Brief Score86/100 (B)68/100 (C)
Semaglutide$239/mo injectable · $219/mo sublingual (quarterly)From $99/mo (starting dose, compounded)
Tirzepatide$399/mo injectable · $299/mo sublingual (quarterly)From $99/mo (starting dose, compounded)
Coverage40 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

MadeMed: Publishes one price per route that holds at every dose — the cleanest dose-to-price mapping we track.

Southern Vitality and Weight Loss: New to the tracker on 1 August 2026. The published line reads From $99/mo (starting dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.